The GLP-1 Strategy Question
GLP-1s changed the bariatric landscape overnight. The question isn’t whether to adapt — it’s how.
Surgical volume has been flat-to-down for five years. Semaglutide and tirzepatide gave every PCP and endocrinologist a “try this first” option that delays or eliminates the surgical referral. The referral pipeline that built your practice isn’t broken — it’s been rerouted. And the practices that figure out where it went are the ones that will grow through this.
What Actually Happened
GLP-1s didn’t kill demand. They rerouted it.
The narrative most bariatric surgeons tell themselves is that GLP-1s are stealing their patients. That’s not quite right. What GLP-1s actually did is expand the metabolic care market dramatically — and capture the front end of it.
There are more patients seeking help with obesity today than at any point in history. GLP-1 prescribing has destigmatized weight management, normalized the idea that obesity is a medical condition worth treating, and brought millions of patients into the metabolic care pipeline who never would have considered intervention before.
The problem for bariatric surgeons isn’t that demand disappeared. It’s that demand is being intercepted earlier — by PCPs, by endocrinologists, by telehealth platforms, by direct-to-consumer GLP-1 services. By the time a patient reaches the point where surgery becomes the conversation, someone else has been managing their metabolic care for months or years. And that someone else gets the referral loyalty.
Meanwhile, the bariatric practice carries the same fixed costs it always has — OR block time, staff, equipment, facility leases — spread across fewer cases. The economics haven’t just shifted. For many practices, they’ve inverted.
Two Strategies, Very Different Outcomes
The wrong response vs. the right one
Waiting it out
Hoping the GLP-1 trend peaks and referral patterns return to normal. They won’t. The medications are getting more effective, the insurance coverage is expanding, and the prescribing is becoming more routine every quarter.
Cutting costs
Reducing staff, renegotiating vendor contracts, squeezing operational efficiency. This preserves margin temporarily but doesn’t address the volume problem. You can’t cut your way to growth.
Competing on price
Offering cash-pay surgery deals, discounted self-pay packages, aggressive financing. This attracts the most price-sensitive patients and compresses margins on every case.
Marketing harder for the same patient
Increasing ad spend to capture the shrinking pool of patients who are already surgery-ready. Cost-per-lead climbs. Conversion rates fall. The math gets worse.
Integrating GLP-1 prescribing
Adding medical weight loss services as a front-door offering. Non-surgical patients become revenue-generating. Surgical candidates get pre-operatively optimized, improving outcomes and conversion rates.
Building the full metabolic continuum
Positioning as the comprehensive metabolic health destination — not just a surgical center. GLP-1 management, nutrition, behavioral health, remote monitoring, and surgery when appropriate.
Owning the referral relationship
When a PCP’s patient isn’t responding to GLP-1 therapy alone, the surgeon who’s already managing metabolic patients gets the surgical referral. Not the surgeon waiting for the phone to ring.
Creating recurring post-surgical revenue
Every surgical patient enters a structured long-term care program — remote monitoring, wellness subscriptions, ongoing support — generating 18 to 24 months of additional revenue per case.
The Integrated Model
The practices capturing market share right now
The bariatric programs that are growing in 2026 have stopped thinking of themselves as surgical practices. They’ve become metabolic health practices that also do surgery.
That distinction matters. A surgical practice waits for referrals from physicians who have a patient that failed medical management. A metabolic health practice manages the medical treatment itself — and converts to surgery when the clinical picture warrants it, on their own timeline, with their own patient.
Patients enter the practice for medical weight loss. Some achieve their goals with medication alone. Others plateau, experience side effects, or have comorbidities that make surgery the better long-term option. Either way, they’re your patients — and you’re generating revenue from day one, not just when they reach the OR.
When a patient does move to surgery, the transition is seamless — same practice, same care team, same medical record. Pre-surgical optimization is already done because the practice has been managing the patient’s metabolic health for months.
Remote monitoring, wellness programs, lab management, supplement dispensing, adjunct GLP-1 prescribing for post-op patients who need it. The global period ends at day 90. The revenue relationship doesn’t.
The insight the top practices have internalized is counterintuitive: GLP-1s aren’t stealing patients from surgery. They’re creating a larger pool of metabolically-engaged patients, some of whom will ultimately need surgery — and the practice that manages their GLP-1 journey is the one that earns the surgical case.
Get in Touch
The practices that figure this out in the next 12 months will define the next era of bariatric medicine.
The ones that don’t will spend the next five years watching their surgical volume decline and wondering where their patients went.
The patients didn’t disappear. They’re being managed by someone else. The question is whether you’re going to be that someone — or keep waiting for a referral that’s increasingly going to a different address.
Talk to Lindsay about your GLP-1 strategy